Fluticasone: Uses, Dosage & Side Effects
A potent inhaled corticosteroid for prevention and long-term control of asthma, COPD management, and treatment of allergic rhinitis
Fluticasone propionate is a potent synthetic corticosteroid used primarily as an inhaled therapy for the prevention and long-term control of asthma and as a nasal spray for allergic rhinitis. It belongs to the class of trifluorinated glucocorticoids and has the highest glucocorticoid receptor binding affinity among commonly used inhaled corticosteroids. Fluticasone works by reducing inflammation in the airways and nasal passages. It takes 4 to 7 days to reach full therapeutic effect and must be used regularly, even when symptoms are absent. It is not a rescue medication and does not provide immediate relief during an acute asthma attack.
Quick Facts: Fluticasone
Key Takeaways
- Fluticasone propionate is one of the most potent inhaled corticosteroids available, with the highest glucocorticoid receptor binding affinity, delivering strong local anti-inflammatory effects while minimizing systemic exposure due to negligible oral bioavailability (<1%).
- It is a preventive (controller) medication for asthma and must be used regularly as prescribed; it takes 4 to 7 days to reach full effect and does not relieve acute asthma attacks—a separate rescue inhaler (such as salbutamol) is needed for that.
- Always rinse your mouth with water and spit out after using a fluticasone inhaler to prevent oral thrush (candidiasis) and hoarseness, which are the most common side effects.
- Long-term use of high-dose inhaled fluticasone may carry risks including adrenal suppression, decreased bone density, cataracts, glaucoma, and growth retardation in children; your doctor will prescribe the lowest effective dose.
- Fluticasone has important drug interactions with strong CYP3A4 inhibitors (including ritonavir, ketoconazole, and cobicistat) that can dramatically increase systemic corticosteroid exposure and cause Cushing syndrome or adrenal suppression.
What Is Fluticasone and What Is It Used For?
Fluticasone propionate is a potent synthetic trifluorinated glucocorticoid that has been a cornerstone of respiratory medicine since its approval in the early 1990s. Developed by Glaxo Wellcome (now GlaxoSmithKline), fluticasone propionate was specifically designed to provide maximum anti-inflammatory potency at the site of action with minimal systemic absorption. It is one of the most widely prescribed inhaled corticosteroids worldwide and is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its critical importance in global asthma management.
The medication exerts its therapeutic effects by binding to intracellular glucocorticoid receptors with exceptionally high affinity—approximately 18 times that of dexamethasone and 1.5 times that of budesonide. Once the fluticasone-receptor complex translocates to the cell nucleus, it modulates gene transcription to suppress the production of multiple inflammatory mediators. This includes reduced synthesis of pro-inflammatory cytokines (interleukins IL-1, IL-4, IL-5, IL-6, IL-8, and tumor necrosis factor-alpha), decreased leukotriene and prostaglandin production, inhibition of inflammatory cell recruitment and activation (including eosinophils, mast cells, lymphocytes, and macrophages), and reduced vascular permeability. The result is a comprehensive suppression of both the early and late phases of the allergic inflammatory response in the airways.
A defining pharmacological feature of fluticasone propionate is its exceptionally low oral bioavailability of less than 1%. This means that any drug swallowed after inhalation is almost entirely inactivated during first-pass metabolism in the liver by the cytochrome P450 enzyme CYP3A4. Even the fraction that reaches the systemic circulation through pulmonary absorption is rapidly cleared, with a plasma half-life of approximately 7.8 hours. This pharmacokinetic profile ensures potent local anti-inflammatory action with significantly fewer systemic side effects compared to oral corticosteroids such as prednisolone, making fluticasone a preferred choice for long-term maintenance therapy.
Inhaled Fluticasone for Asthma
Inhaled fluticasone propionate is a first-line controller therapy for persistent asthma across all severity levels. The Global Initiative for Asthma (GINA) 2024 report recommends inhaled corticosteroids as the foundation of asthma management in Steps 2 through 5. Available as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), inhaled fluticasone reduces airway inflammation, decreases the frequency and severity of asthma exacerbations, improves lung function parameters (FEV1 and peak expiratory flow), reduces bronchial hyperresponsiveness, and decreases the need for rescue bronchodilator use. The typical onset of benefit occurs within 24 hours, but full therapeutic effect generally requires 4 to 7 days of regular use, with maximum benefit achieved after 1 to 2 weeks of consistent daily dosing.
The British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN) asthma guideline and NICE guidance both recommend starting inhaled corticosteroid therapy at the dose appropriate to the severity of the disease, with the aim of achieving and maintaining asthma control at the lowest possible dose. Patients who find it difficult to coordinate actuation and inhalation with a standard MDI may benefit from using a spacer device (such as a Volumatic chamber), which improves drug delivery to the lungs and reduces oropharyngeal deposition, thereby lowering the risk of local side effects such as oral candidiasis.
Inhaled Fluticasone for COPD
In chronic obstructive pulmonary disease (COPD), inhaled fluticasone propionate is used in combination with a long-acting beta-2 agonist (LABA) such as salmeterol for patients with frequent exacerbations and significant symptoms despite bronchodilator therapy alone. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2024 report recommends inhaled corticosteroid/LABA combinations for patients in GOLD Groups D and E with elevated blood eosinophil counts (greater than 300 cells per microlitre). It is important to note that pneumonia is a recognized risk with inhaled fluticasone use in COPD patients, and this should be weighed against the exacerbation prevention benefit. Fluticasone is not recommended as monotherapy for COPD.
Fluticasone Nasal Spray for Allergic Rhinitis
Fluticasone propionate nasal spray is used to treat seasonal and perennial allergic rhinitis. It effectively reduces nasal congestion, sneezing, rhinorrhea (runny nose), nasal itching, and ocular symptoms. International guidelines including ARIA (Allergic Rhinitis and its Impact on Asthma) recommend intranasal corticosteroids as the most effective single-agent pharmacotherapy for moderate-to-severe allergic rhinitis. The nasal spray delivers fluticasone directly to the nasal mucosa, with minimal systemic absorption. In some markets, lower-dose fluticasone nasal sprays are available without prescription for the short-term treatment of seasonal allergy symptoms in adults. A closely related compound, fluticasone furoate (marketed as Avamys or Veramyst), has a different molecular structure optimized for once-daily nasal dosing.
What Should You Know Before Taking Fluticasone?
Before starting fluticasone propionate, it is essential that your prescribing physician has a complete picture of your medical history, current medications, and any known allergies. Several conditions and circumstances require particular caution or may affect how fluticasone is used. Understanding these precautions helps ensure safe and effective treatment.
Contraindications
Fluticasone propionate is contraindicated in individuals with a known hypersensitivity (allergy) to fluticasone propionate or any of the excipients in the formulation. Allergic reactions can range from skin rash and urticaria to severe anaphylaxis with facial, lip, tongue, or throat swelling, and difficulty breathing. If you experience any signs of an allergic reaction after using fluticasone, discontinue use immediately and seek medical attention.
Fluticasone inhalers are intended for the regular prevention and control of asthma. They are not designed for the relief of acute asthma attacks or status asthmaticus, which require rapid-acting bronchodilators such as salbutamol (albuterol). Patients should always have their short-acting rescue inhaler available for breakthrough symptoms.
Your breathing or wheezing worsens immediately after using a dose of inhaled fluticasone. This paradoxical bronchospasm is rare but requires immediate treatment with a rescue bronchodilator and urgent medical evaluation.
Warnings and Precautions
Inform your doctor before using fluticasone if you have ever been treated for tuberculosis (TB), as corticosteroids can potentially reactivate latent TB infection. Your doctor may need to monitor you more closely or initiate concurrent TB treatment. Patients with active or quiescent pulmonary tuberculosis should use inhaled fluticasone only under close medical supervision.
If you have diabetes mellitus, be aware that fluticasone, particularly at higher doses, may elevate blood glucose levels. Regular blood glucose monitoring may be advisable when initiating or adjusting inhaled corticosteroid therapy. This effect is generally more pronounced with oral corticosteroids but can occur with high-dose inhaled therapy.
Prolonged use of high-dose inhaled fluticasone can lead to systemic corticosteroid effects. These may include:
- Adrenal suppression and acute adrenal crisis: The hypothalamic-pituitary-adrenal (HPA) axis may become suppressed, particularly in patients using high doses for extended periods or those transitioning from oral corticosteroids. Symptoms of adrenal insufficiency include fatigue, nausea, vomiting, headache, abdominal pain, and dizziness. Adrenal crisis can be triggered by physiological stress such as surgery, trauma, or severe infection.
- Cushing syndrome: Weight gain, moon face, central obesity, skin thinning, and striae may develop with chronic high-dose use.
- Decreased bone mineral density: Long-term use may contribute to osteoporosis, particularly in post-menopausal women and elderly patients.
- Ocular effects: Cataracts and glaucoma (increased intraocular pressure) have been reported. Regular eye examinations may be recommended for long-term users.
- Growth retardation in children: Inhaled corticosteroids may reduce growth velocity in children and adolescents. Height should be monitored regularly, and the dose should be reduced to the lowest effective level.
Contact your doctor if you experience blurred vision or other visual disturbances while using fluticasone, as these may be symptoms of cataracts or glaucoma requiring evaluation.
Pregnancy and Breastfeeding
Fluticasone propionate should be used during pregnancy only when the potential benefit to the mother outweighs the potential risk to the fetus. Animal reproductive studies have shown adverse effects at high systemic exposures, although relevance to human therapeutic doses is uncertain. Importantly, uncontrolled asthma during pregnancy poses significant risks to both mother and baby, including pre-eclampsia, premature delivery, and low birth weight. International guidelines (GINA, BTS/SIGN) generally recommend maintaining asthma control with inhaled corticosteroids during pregnancy, as the risks of uncontrolled asthma typically outweigh the potential risks of inhaled corticosteroid use.
It is not known whether fluticasone propionate is excreted into human breast milk, although other corticosteroids have been detected in breast milk. Given the very low systemic bioavailability of inhaled fluticasone, the amount reaching breast milk is expected to be negligible. The decision to continue breastfeeding during fluticasone treatment should be made in consultation with your healthcare provider, weighing the benefits of breastfeeding against the potential risk to the infant.
Driving and Operating Machinery
Fluticasone propionate is not expected to affect the ability to drive or operate machinery. No studies on driving performance have been conducted, and the pharmacological profile of the drug does not suggest any impairment of alertness or psychomotor function. However, patients should be aware of their overall health condition and any concurrent medications that may affect their ability to perform these activities safely.
How Does Fluticasone Interact with Other Drugs?
Drug interactions with fluticasone propionate primarily involve the cytochrome P450 3A4 (CYP3A4) metabolic pathway. Since fluticasone is extensively metabolized by CYP3A4 in the liver, any drug that strongly inhibits this enzyme can significantly reduce fluticasone clearance, leading to increased systemic exposure and a higher risk of corticosteroid side effects. Understanding these interactions is crucial for both healthcare providers and patients.
Major Interactions
The most clinically significant interactions occur with potent CYP3A4 inhibitors. The combination of fluticasone with ritonavir (an HIV protease inhibitor and pharmacokinetic booster) is particularly dangerous and is generally contraindicated unless the potential benefit clearly outweighs the risk. Published case reports have documented Cushing syndrome and adrenal suppression in patients taking inhaled or nasal fluticasone concurrently with ritonavir, even at standard inhaled doses. The same risk applies to other potent CYP3A4 inhibitors used in HIV therapy, including cobicistat, atazanavir, indinavir, nelfinavir, and saquinavir.
Ketoconazole, a potent antifungal CYP3A4 inhibitor, has been shown in pharmacokinetic studies to increase systemic fluticasone propionate exposure by approximately 150%. This combination should be avoided or used with extreme caution, with close monitoring for signs of corticosteroid excess. Other azole antifungals such as itraconazole carry a similar, though potentially lesser, risk.
Moderate Interactions
Macrolide antibiotics including clarithromycin and telithromycin are moderate CYP3A4 inhibitors that can increase fluticasone exposure. If co-administration is necessary, your doctor should monitor you closely for signs of systemic corticosteroid effects. Erythromycin is a weaker inhibitor and generally poses less concern, though caution is still advised.
| Interacting Drug | Drug Class | Severity | Effect |
|---|---|---|---|
| Ritonavir | HIV protease inhibitor | Major | Dramatically increases fluticasone levels; risk of Cushing syndrome and adrenal suppression. Avoid combination. |
| Cobicistat | Pharmacokinetic enhancer | Major | Potent CYP3A4 inhibitor; significantly increases systemic corticosteroid exposure. Avoid combination. |
| Ketoconazole | Azole antifungal | Major | Increases fluticasone AUC by ~150%. Avoid or use with extreme caution. |
| Itraconazole | Azole antifungal | Moderate | CYP3A4 inhibitor; may increase systemic fluticasone exposure. Monitor closely. |
| Clarithromycin | Macrolide antibiotic | Moderate | Moderate CYP3A4 inhibitor; increases fluticasone levels. Monitor for systemic steroid effects. |
| Telithromycin | Ketolide antibiotic | Moderate | CYP3A4 inhibitor; may increase systemic fluticasone exposure. Monitor closely. |
| Atazanavir, Indinavir, Nelfinavir, Saquinavir | HIV protease inhibitors | Major | Strong CYP3A4 inhibitors; risk of iatrogenic Cushing syndrome. Avoid or use alternative corticosteroid. |
Transitioning from Oral Corticosteroids
Patients who are transitioning from oral corticosteroid therapy (such as prednisolone tablets) to inhaled fluticasone require special attention. Oral corticosteroids suppress the hypothalamic-pituitary-adrenal (HPA) axis, and this suppression may persist for a considerable time after discontinuation. During the transition period, patients remain at risk of adrenal insufficiency, particularly during physiological stress (severe illness, surgery, trauma). Your doctor should taper the oral corticosteroid dose gradually and may recommend that you carry a steroid alert card. Supplementary systemic corticosteroids may be required during periods of stress until adrenal function has fully recovered.
What Is the Correct Dosage of Fluticasone?
Fluticasone propionate is available in multiple strengths to allow individualized dosing. The prescribing physician determines the appropriate strength and dose based on the severity of the condition, the patient's current treatment, and the individual response. The fundamental principle is to use the lowest dose that maintains effective symptom control. Below are the general dosage guidelines based on international recommendations.
Adults and Adolescents (16 Years and Over)
Inhaled Fluticasone for Asthma (MDI)
Mild asthma: 100–250 mcg twice daily
Moderate asthma: 250–500 mcg twice daily
Severe asthma: 500–1000 mcg twice daily
The starting dose should match the severity of the disease. Doses are typically taken morning and evening, approximately 12 hours apart. The dose may be adjusted up or down based on the individual response, aiming for the lowest dose that achieves asthma control.
Fluticasone Nasal Spray for Allergic Rhinitis
Adults: 2 sprays (100 mcg) per nostril once daily, preferably in the morning. May be reduced to 1 spray per nostril once daily for maintenance.
Maximum dose: 200 mcg (2 sprays per nostril) once daily.
Children
The inhaler formulations described in this article (125 mcg and 250 mcg MDIs) are generally not recommended for children under 16 years of age. Lower-strength formulations (50 mcg per dose) may be available for children aged 4 and above in certain markets, typically prescribed at 50–100 mcg twice daily. For nasal spray, children aged 4–11 years typically use 1 spray (50 mcg) per nostril once daily. Paediatric dosing should always be determined by the prescribing physician, and growth should be monitored regularly in children receiving long-term inhaled corticosteroid therapy.
Elderly Patients
No specific dose adjustment is required for elderly patients. Standard adult dosing applies. However, elderly patients may be more susceptible to systemic effects of corticosteroids, including osteoporosis and adrenal suppression, and should be monitored accordingly. Good inhaler technique is essential and should be assessed regularly, as physical limitations such as reduced hand strength or coordination may impair proper device use.
| Indication | Patient Group | Typical Dose | Frequency |
|---|---|---|---|
| Mild asthma | Adults ≥ 16 years | 100–250 mcg | Twice daily |
| Moderate asthma | Adults ≥ 16 years | 250–500 mcg | Twice daily |
| Severe asthma | Adults ≥ 16 years | 500–1000 mcg | Twice daily |
| Allergic rhinitis | Adults ≥ 12 years | 100 mcg per nostril | Once daily |
| Allergic rhinitis | Children 4–11 years | 50 mcg per nostril | Once daily |
Missed Dose
If you forget to take a dose of fluticasone, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Missing an occasional dose is unlikely to cause significant problems, but regular daily use is essential for maintaining asthma control. Setting a daily alarm or keeping the inhaler next to a habitual activity (such as brushing your teeth) can help establish a consistent routine.
Overdose
Acute overdose with inhaled fluticasone propionate is unlikely to cause immediate harm. Taking substantially more than the prescribed dose over a prolonged period, however, may lead to hypothalamic-pituitary-adrenal axis suppression. If significant overdose is suspected, contact your healthcare provider or a poison control centre for guidance. Treatment is supportive; the dose should be reduced to the recommended level, and adrenal function may need to be monitored. Patients who have been taking excessive doses should not abruptly stop treatment, as this can precipitate acute adrenal insufficiency.
How to Use the Inhaler Correctly
Proper inhaler technique is critical for effective drug delivery to the lungs. Studies consistently show that a large proportion of patients use their inhalers incorrectly, reducing therapeutic efficacy. The following steps describe the correct technique for a metered-dose inhaler (MDI):
- Prepare: Remove the mouthpiece cover and inspect the mouthpiece for foreign objects. Shake the inhaler well (4–5 times) before each use.
- Prime if necessary: If the inhaler is new or has not been used for a week or more, release two test sprays into the air away from your face.
- Breathe out: Hold the inhaler upright with your thumb at the base. Breathe out gently and completely—do not breathe into the inhaler.
- Inhale: Place the mouthpiece between your teeth and close your lips around it (do not bite). Begin to breathe in slowly and deeply through your mouth. As you start to inhale, press down firmly on the canister to release one puff.
- Hold your breath: Remove the inhaler from your mouth. Hold your breath for about 10 seconds or as long as is comfortable.
- Wait: If a second puff is prescribed, wait approximately 30 seconds before repeating steps 3–5.
- Rinse: After your final dose, rinse your mouth thoroughly with water and spit out to prevent oral thrush. You may also brush your teeth.
- Replace the cap: Always replace the mouthpiece cover after use to protect against dust and debris.
Patients who find it difficult to coordinate pressing the canister and breathing in simultaneously should use a spacer device (such as a Volumatic chamber). A spacer improves drug delivery to the lungs, reduces the need for perfect coordination, and significantly decreases drug deposition in the mouth and throat—lowering the risk of oral candidiasis and hoarseness. Children and elderly patients particularly benefit from spacer use.
Cleaning the Inhaler
To prevent blockage and ensure consistent dose delivery, clean the inhaler at least once a week. Remove the mouthpiece cover. Wipe the inside and outside of the mouthpiece and the plastic housing with a dry cloth or tissue. Do not place the metal canister in water. Replace the mouthpiece cover after cleaning.
What Are the Side Effects of Fluticasone?
Like all medications, fluticasone propionate can cause side effects, although not everyone will experience them. Most side effects of inhaled fluticasone are local (affecting the mouth, throat, and airways) and can be minimized with good inhaler technique and mouth rinsing after use. Systemic side effects become more likely with higher doses used over prolonged periods. The side effects listed below are categorized by frequency according to standard pharmacovigilance conventions used by the European Medicines Agency (EMA).
You experience signs of a severe allergic reaction (anaphylaxis): swelling of the face, lips, tongue, or throat; difficulty breathing; widespread skin rash or hives; feeling faint or dizzy. Also seek urgent help if your breathing or wheezing suddenly worsens after using the inhaler (paradoxical bronchospasm).
Very Common
Affects more than 1 in 10 people
- Oral thrush (candidiasis) — fungal infection of the mouth and throat
Common
Affects 1 in 10 to 1 in 100 people
- Hoarseness (dysphonia) and throat irritation
- Easy bruising
- Pneumonia (in patients with COPD)
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Allergic skin reactions (rash, redness, itching, urticaria)
Very Rare
Affects fewer than 1 in 10,000 people
- Anaphylaxis (severe life-threatening allergic reaction)
- Sleep disturbances, restlessness, hyperactivity, and irritability (more common in children)
- Joint pain
- Gastrointestinal disturbances
- Elevated blood glucose (hyperglycaemia)
- Cushing syndrome, adrenal suppression, and acute adrenal crisis (with prolonged high-dose use)
- Decreased bone mineral density (osteoporosis)
- Cataracts and glaucoma
- Growth retardation in children and adolescents
Unknown Frequency
Frequency cannot be estimated from available data
- Depression
- Anxiety, restlessness, or nervousness (more common in children)
- Nosebleeds (epistaxis)
- Blurred vision
Managing Local Side Effects
Oral candidiasis (thrush) is the most frequent side effect and presents as white patches on the tongue, inner cheeks, or throat, sometimes accompanied by soreness or altered taste. The risk is significantly reduced by rinsing the mouth with water and spitting out after each inhaler use, using a spacer device with metered-dose inhalers, and using the lowest effective dose. If oral thrush develops, it can usually be treated with antifungal lozenges or oral suspension (such as nystatin or miconazole) without needing to discontinue the inhaler.
Hoarseness (dysphonia) results from corticosteroid deposition on the vocal cords. It typically resolves with dose reduction or temporary discontinuation. Using a spacer device and good inhaler technique can help minimize this effect. Patients who use their voice professionally (singers, teachers, public speakers) should discuss preventive strategies with their healthcare provider.
Pneumonia Risk in COPD
Large clinical trials including TORCH (Towards a Revolution in COPD Health) and INSPIRE have demonstrated an increased incidence of pneumonia in COPD patients using inhaled fluticasone propionate compared to placebo or bronchodilator therapy alone. The GOLD 2024 report acknowledges this risk and recommends that the decision to use inhaled corticosteroids in COPD should balance the benefit of exacerbation reduction against the pneumonia risk. Risk factors for pneumonia in COPD patients using ICS include older age, lower BMI, lower FEV1, prior pneumonia history, and concurrent use of oral corticosteroids. If you develop symptoms of pneumonia while taking fluticasone for COPD—such as fever, chills, increased sputum production, change in sputum colour, worsening cough, or increased breathlessness—contact your doctor promptly.
Reporting Side Effects
If you experience any side effects—including those not listed above—talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national pharmacovigilance authority (for example, the Yellow Card Scheme in the UK, MedWatch in the United States, or your country's equivalent). Reporting side effects contributes to the ongoing monitoring of drug safety.
How Should You Store Fluticasone?
Proper storage of fluticasone propionate inhalers ensures that the medication remains effective throughout its shelf life. The pressurized canister contains the drug suspension propelled by a hydrofluoroalkane (HFA) propellant, and improper storage can affect both the drug integrity and canister function.
- Temperature: Store at or below 30°C (86°F). Do not expose to temperatures exceeding 50°C (122°F). Do not refrigerate or freeze. Protect from frost and direct sunlight.
- Canister care: The contents are under pressure. Do not puncture, crush, or incinerate the canister, even when apparently empty.
- Cold weather: If the inhaler has been exposed to cold temperatures, remove the metal canister from the plastic housing and warm it between your hands for a few minutes before use. Do not use any external heat source.
- Children: Keep out of the sight and reach of children.
- Expiry date: Do not use the inhaler after the expiry date printed on the label and carton. The expiry date refers to the last day of the stated month.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired inhalers to your pharmacy for safe disposal, which protects the environment.
Clean the inhaler weekly according to the manufacturer's instructions to prevent the mouthpiece from becoming blocked, which could reduce the amount of medication delivered with each puff.
What Does Fluticasone Contain?
Fluticasone propionate metered-dose inhalers have a simple formulation consisting of the active drug suspended in a propellant. Understanding the composition is helpful for patients with specific allergies or sensitivities to pharmaceutical excipients.
Active substance: Fluticasone propionate. The metered valve delivers 125 or 250 micrograms per actuation. The actual dose leaving the mouthpiece (delivered dose) is slightly lower than the metered dose—approximately 110 or 227 micrograms respectively—due to normal drug deposition in the actuator.
Propellant: Norflurane (HFA-134a), a hydrofluoroalkane propellant used in modern MDIs as a replacement for older chlorofluorocarbon (CFC) propellants. Norflurane has a lower global warming potential than some alternative propellants and does not deplete the ozone layer. Each inhaler typically contains 12.5 grams of HFA-134a. Pharmaceutical companies are actively developing inhalers using propellants with even lower environmental impact.
Physical appearance: The inhaler consists of a white suspension in a fluorocarbon-polymer-coated aluminium canister fitted with a metering valve, actuator, and mouthpiece cover. Each canister delivers 120 metered doses.
Available pack sizes: Single packs containing one canister (120 doses), multipacks of 2 or 3 single canisters, and hospital packs of 10 canisters. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Fluticasone
Fluticasone propionate is a corticosteroid used to prevent and control asthma symptoms (as an inhaler), treat allergic rhinitis and nasal congestion (as a nasal spray), and manage various inflammatory skin conditions (as a cream or ointment). As an inhaler, it reduces inflammation in the airways to prevent asthma attacks, but it does not relieve acute attacks—a separate rescue inhaler such as salbutamol is needed for that purpose.
Inhaled fluticasone may begin to show improvement within 24 hours, but full therapeutic benefit typically requires 4 to 7 days of regular use, with some patients needing up to 2 weeks for maximum effect. Fluticasone nasal spray usually starts to relieve allergy symptoms within 12 hours, with full improvement after several days. It is essential to use fluticasone regularly as prescribed, even when you feel well, for optimal results.
Flonase and Flovent are brand names for fluticasone propionate products. Flovent is the brand name for the inhaled formulation used for asthma (available primarily in North America). Flonase is the brand name for the nasal spray used for allergic rhinitis. Other brand names include Flixotide (inhaler) and Flixonase (nasal spray) in many European and international markets. They all contain the same active ingredient, fluticasone propionate, but in different formulations and delivery devices optimized for different conditions.
You should not stop taking inhaled fluticasone suddenly without medical advice, especially if you have been using high doses for a prolonged period. Abrupt discontinuation can lead to worsening of asthma symptoms and, in patients who have been on long-term high-dose therapy, may cause adrenal insufficiency. Symptoms of adrenal crisis include severe fatigue, nausea, vomiting, headache, low blood sugar, and seizures. Your doctor will typically reduce your dose gradually if discontinuation is needed. Always consult your healthcare provider before making changes to your treatment regimen.
Fluticasone propionate and fluticasone furoate are two distinct compounds with different molecular structures. Fluticasone furoate (marketed as Avamys/Veramyst for nasal use and Arnuity Ellipta/Relvar Ellipta for inhalation) has an enhanced binding affinity for the glucocorticoid receptor and a longer duration of action, allowing for once-daily dosing. Fluticasone propionate typically requires twice-daily dosing for asthma. Both compounds have similar safety profiles, but they are not interchangeable on a microgram-for-microgram basis due to differences in potency and pharmacokinetics. Your doctor will choose the most appropriate formulation for your condition.
Yes, always rinse your mouth thoroughly with water and spit out after using a fluticasone inhaler. This is one of the most important steps to prevent oral thrush (candidiasis) and hoarseness, which are the most common side effects. You may also brush your teeth after rinsing. Do not swallow the rinse water. Using a spacer device with your metered-dose inhaler further reduces the amount of drug deposited in the mouth and throat, providing additional protection against these local side effects.
References
- 1 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024. Available at: ginasthma.org
- 2 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2024. Available at: goldcopd.org
- 3 European Medicines Agency (EMA). Fluticasone Propionate — Summary of Product Characteristics. EMA/CHMP. 2024.
- 4 British National Formulary (BNF). Fluticasone Propionate. NICE Evidence Services. 2024. Available at: bnf.nice.org.uk
- 5 National Institute for Health and Care Excellence (NICE). Asthma: Diagnosis, Monitoring and Chronic Asthma Management. NICE Guideline NG80. Updated 2024.
- 6 British Thoracic Society / Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. SIGN 158. 2024.
- 7 World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
- 8 Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH trial). N Engl J Med. 2007;356(8):775–789.
- 9 Brézin AP, et al. Inhaled corticosteroids and risk of cataracts and glaucoma. Ophthalmology. 2019;126(10):1403–1414.
- 10 Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050.
- 11 ARIA (Allergic Rhinitis and its Impact on Asthma) Guidelines. 2023 Revision. Available at: aria.whorg.org
- 12 U.S. Food and Drug Administration (FDA). Fluticasone Propionate Prescribing Information. FDA. 2024.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specializing in clinical pharmacology, pulmonology, and allergy and immunology. Our editorial process follows international medical standards and the GRADE evidence framework.
iMedic Medical Editorial Team — specialists in clinical pharmacology and respiratory medicine with documented academic and clinical experience.
iMedic Medical Review Board — independent panel of medical experts reviewing content according to WHO, EMA, FDA, BNF, and GINA guidelines.
This article is based on Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials). Sources include GINA 2024, GOLD 2024, EMA SmPC, FDA prescribing information, BNF monographs, and peer-reviewed clinical trials. No commercial funding or pharmaceutical company sponsorship was involved in the creation of this content.